Drug Trial Radar · NCT01763866
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,067
Actual
Start
Jan 15, 2013
Primary completion
Nov 12, 2013
Study completion Dec 4, 2013
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Conditions
- Hyperlipidemia
Interventions
EvolocumabBiological
Administered by subcutaneous injection
EzetimibeDrug
Administered orally once a day
Placebo to EvolocumabDrug
Administered by subcutaneous injection
Placebo to EzetimibeDrug
Administered orally once a day
AtorvastatinDrug
Administered orally once a day
RosuvastatinDrug
Administered orally once a day
SimvastatinDrug
Administered orally once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12Time frame: Baseline and Week 12
- Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12Time frame: Baseline and Weeks 10 and 12
Locations
244 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Glendale, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Carmichael, California
Research Site
Encino, California
Research Site
Long Beach, California
Research Site
Newport Beach, California
Research Site
San Diego, California
Research Site
Santa Ana, California
Research Site
Santa Rosa, California
Research Site
Thousand Oaks, California
Research Site
Torrance, California
Research Site
Tustin, California
Research Site
Westlake Village, California
Research Site
Littleton, Colorado
Research Site
Daytona Beach, Florida
Research Site
Jacksonville, Florida
Research Site
Melbourne, Florida
Research Site
Miami, Florida
Research Site
Port Charlotte, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Boise, Idaho
Research Site
Hammond, Indiana
Research Site
Indianapolis, Indiana
Research Site
Valparaiso, Indiana
Research Site
Iowa City, Iowa
Research Site
Crestview Hills, Kentucky
Research Site
Monroe, Louisiana
Research Site
Auburn, Maine
Research Site
Bangor, Maine
Research Site
Portland, Maine
Research Site
Baltimore, Maryland
Research Site
Ypsilanti, Michigan
Research Site
Tupelo, Mississippi
Research Site
Billings, Montana
Research Site
Voorhees Township, New Jersey
Research Site
Manlius, New York
Research Site
Rochester, New York
Showing 40 of 244 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.